Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

PHASE3CompletedINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

September 30, 2008

Conditions
HIV Infections
Interventions
DRUG

Tipranavir

DRUG

Ritonavir(r)

DRUG

Comparator Protease Inhibitor (CPI)

Trial Locations (117)

Unknown

1182.12.11016 Boehringer Ingelheim Investigational Site, Halifax

1182.12.11012 Boehringer Ingelheim Investigational Site, Hamilton

1182.12.11001 Boehringer Ingelheim Investigational Site, Ottawa

1182.12.11004 Boehringer Ingelheim Investigational Site, Toronto

1182.12.11006 Boehringer Ingelheim Investigational Site, Toronto

1182.12.11009 Boehringer Ingelheim Investigational Site, Toronto

1182.12.11014 Boehringer Ingelheim Investigational Site, Toronto

1182.12.11015 Boehringer Ingelheim Investigational Site, Monteal

1182.12.11003 Boehringer Ingelheim Investigational Site, Montreal

1182.12.11007 Boehringer Ingelheim Investigational Site, Montreal

1182.12.11013 Boehringer Ingelheim Investigational Site, Montreal

1182.12.60 Boehringer Ingelheim Investigational Site, Santurce

1182.12.62 Boehringer Ingelheim Investigational Site, Phoenix

1182.12.108 El Rio SIA, Tucson

1182.12.9 Boehringer Ingelheim Investigational Site, Berkeley

1182.12.23 Boehringer Ingelheim Investigational Site, Beverly Hills

1182.12.12 Boehringer Ingelheim Investigational Site, Fountain Valley

1182.12.76 Boehringer Ingelheim Investigational Site, Long Beach

1182.12.1 Boehringer Ingelheim Investigational Site, Los Angeles

1182.12.59 David Geffen School of Medicine at UCLA, Los Angeles

1182.12.82 Boehringer Ingelheim Investigational Site, Los Angeles

1182.12.97 Boehringer Ingelheim Investigational Site, Los Angeles

1182.12.69 UC Davis Medical Center, Sacramento

1182.12.89 Boehringer Ingelheim Investigational Site, San Diego

1182.12.99 Boehringer Ingelheim Investigational Site, San Diego

1182.12.25 Boehringer Ingelheim Investigational Site, San Francisco

1182.12.5 Boehringer Ingelheim Investigational Site, San Francisco

1182.12.53 Boehringer Ingelheim Investigational Site, San Francisco

1182.12.98 University of Colorado Health Sciences Center, Denver

1182.12.7 Boehringer Ingelheim Investigational Site, Norwalk

1182.12.103 Boehringer Ingelheim Investigational Site, Washington D.C.

1182.12.52 Boehringer Ingelheim Investigational Site, Washington D.C.

1182.12.70, Washington D.C.

1182.12.79 Boehringer Ingelheim Investigational Site, Fort Lauderdale

1182.12.77 Boehringer Ingelheim Investigational Site, Fort Myers

1182.12.45 Boehringer Ingelheim Investigational Site, Miami

1182.12.75 CARES Resource, Miami

1182.12.85 Boehringer Ingelheim Investigational Site, Miami

1182.12.93 Boehringer Ingelheim Investigational Site, Miami Beach

1182.12.17 Boehringer Ingelheim Investigational Site, Orlando

1182.12.90 Boehringer Ingelheim Investigational Site, Sarasota

1182.12.63 Boehringer Ingelheim Investigational Site, Tampa

1182.12.78 Boehringer Ingelheim Investigational Site, Tampa

1182.12.94 Infectious Disease Research Institute, Tampa

1182.12.67 Boehringer Ingelheim Investigational Site, Vero Beach

1182.12.123 Infectious Disease Clinics of Emory, Atlanta

1182.12.88 Boehringer Ingelheim Investigational Site, Atlanta

1182.12.72 Boehringer Ingelheim Investigational Site, Decatur

1182.12.47 Boehringer Ingelheim Investigational Site, Macon

1182.12.8 Family Practice Medical Center, Boise

1182.12.105 Boehringer Ingelheim Investigational Site, Chicago

1182.12.3 Boehringer Ingelheim Investigational Site, Chicago

1182.12.49 Boehringer Ingelheim Investigational Site, Chicago

1182.12.32 Boehringer Ingelheim Investigational Site, Indianapolis

1182.12.48 Boehringer Ingelheim Investigational Site, Indianapolis

1182.12.33 Boehringer Ingelheim Investigational Site, Lexington

1182.12.44 Boehringer Ingelheim Investigational Site, Louisville

1182.12.95 Boehringer Ingelheim Investigational Site, New Orleans

1182.12.81 Boehringer Ingelheim Investigational Site, Portland

1182.12.30 Boehringer Ingelheim Investigational Site, Baltimore

1182.12.6 Boehringer Ingelheim Investigational Site, Bethesda

1182.12.100 Boehringer Ingelheim Investigational Site, Boston

1182.12.101 Boehringer Ingelheim Investigational Site, Boston

1182.12.41 Boehringer Ingelheim Investigational Site, Boston

1182.12.61 Boehringer Ingelheim Investigational Site, Springfield

1182.12.13 University of Michigan Health System, Ann Arbor

1182.12.54 Boehringer Ingelheim Investigational Site, Detroit

1182.12.56 Boehringer Ingelheim Investigational Site, Detroit

1182.12.120 Department of Medicine, HIV/AIDS Program, Minneapolis

1182.12.14 Dybedal Center for Clinical Research, Kansas City

1182.12.87 Boehringer Ingelheim Investigational Site, St Louis

1182.12.11 Wellness Center, Las Vegas

1182.12.4 Boehringer Ingelheim Investigational Site, Camden

1182.12.21 Boehringer Ingelheim Investigational Site, East Orange

1182.12.40 Boehringer Ingelheim Investigational Site, Santa Fe

1182.12.68 Boehringer Ingelheim Investigational Site, Albany

1182.12.34 Boehringer Ingelheim Investigational Site, Mount Vernon

1182.12.119 Boehringer Ingelheim Investigational Site, New York

1182.12.22 Boehringer Ingelheim Investigational Site, New York

1182.12.36 Boehringer Ingelheim Investigational Site, New York

1182.12.58 Beth Israel Medical Center, New York

1182.12.96 Boehringer Ingelheim Investigational Site, New York

1182.12.107 Boehringer Ingelheim Investigational Site, Rochester

1182.12.83 Boehringer Ingelheim Investigational Site, Stony Brook

1182.12.43 Boehringer Ingelheim Investigational Site, Valhalla

1182.12.42 Boehringer Ingelheim Investigational Site, Durham

1182.12.46 Boehringer Ingelheim Investigational Site, Huntersville

1182.12.109 Boehringer Ingelheim Investigational Site, Akron

1182.12.24 Boehringer Ingelheim Investigational Site, Cincinnati

1182.12.35 Boehringer Ingelheim Investigational Site, Cleveland

1182.12.65 Ohio State University Medical Center, Columbus

1182.12.80 Infectious Disease Institute Clinical Trials Unit, Oklahoma City

1182.12.114 Pinnacle Health, Harrisburg

1182.12.28 University of Pennsylvania, Philadelphia

1182.12.50 Boehringer Ingelheim Investigational Site, Philadelphia

1182.12.86 The Miriam Hospital, Providence

1182.12.10 Boehringer Ingelheim Investigational Site, Columbia

1182.12.116 Greenville Hospital System, Greenville

1182.12.2 Boehringer Ingelheim Investigational Site, Memphis

1182.12.106 Boehringer Ingelheim Investigational Site, Dallas

1182.12.55 Boehringer Ingelheim Investigational Site, Dallas

1182.12.31 Boehringer Ingelheim Investigational Site, Houston

1182.12.73 Boehringer Ingelheim Investigational Site, Houston

1182.12.26 Boehringer Ingelheim Investigational Site, San Antonio

1182.12.91 Boehringer Ingelheim Investigational Site, Annandale

1182.12.122 VCU Health Systems, Richmond

1182.12.15 Boehringer Ingelheim Investigational Site, Seattle

1182.12.29 Boehringer Ingelheim Investigational Site, Milwaukee

1182.12.1401 St. Vincent's Hospital, Darlinghurst

1182.12.1405 AIDS Research Initiative / Ground Zero, Darlinghurst

1182.12.1407 Holdsworth House General Practice, Darlinghurst

1182.12.1408 407 Doctors Pty Ltd., Darlinghurst

1182.12.1403 Albion Street Centre, Surry Hills

1182.12.1406 Gold Coast Sexual Health Clinic, Miami

1182.12.1404 Alfred Hospital, Melbourne

1182.12.11002 Boehringer Ingelheim Investigational Site, Vancouver

1182.12.11010 Boehringer Ingelheim Investigational Site, Winnipeg

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00054717 - Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST) | Biotech Hunter | Biotech Hunter